Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies.

IF 2.1 4区 医学 Q2 PSYCHOLOGY, CLINICAL Journal of psychoactive drugs Pub Date : 2024-11-06 DOI:10.1080/02791072.2024.2424272
Aleksandra Barstowe, Petri J Kajonius
{"title":"Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies.","authors":"Aleksandra Barstowe, Petri J Kajonius","doi":"10.1080/02791072.2024.2424272","DOIUrl":null,"url":null,"abstract":"<p><p>Psychedelic-assisted therapy is becoming increasingly acknowledged as an effective therapeutic intervention for various psychiatric illnesses. However, the evaluation of masking success is rarely reported in trials. The objective of the present systematic review was to evaluate placebo-control and masking in studies exploring psychedelic-assisted therapy. Nine (k = 9) studies dating between January 2010 and March 2023 were retrieved using six databases, following strict inclusion and exclusion criteria. The results show that almost 78% of the studies had, at best, \"poor\" masking success. At the same time, 60% of active placebo and 75% of inactive placebo studies showed large effect sizes. In other words, masking influences, including benign unmasking, cannot be excluded. We therefore conclude that efficacy of psilocybin, Ayahuasca, or LSD is only one of the possible interpretations of large, positive changes in symptomatology for patients suffering from, for example, alcohol use disorder, anxiety with or without life-threatening disease, anxiety and/or depression with life-threatening cancer, treatment-resistant depression or major depressive disorder. We recommend care be taken to increase successful masking procedures and discuss alternative treatment designs to better control for potential masking influences.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-11"},"PeriodicalIF":2.1000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of psychoactive drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02791072.2024.2424272","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Psychedelic-assisted therapy is becoming increasingly acknowledged as an effective therapeutic intervention for various psychiatric illnesses. However, the evaluation of masking success is rarely reported in trials. The objective of the present systematic review was to evaluate placebo-control and masking in studies exploring psychedelic-assisted therapy. Nine (k = 9) studies dating between January 2010 and March 2023 were retrieved using six databases, following strict inclusion and exclusion criteria. The results show that almost 78% of the studies had, at best, "poor" masking success. At the same time, 60% of active placebo and 75% of inactive placebo studies showed large effect sizes. In other words, masking influences, including benign unmasking, cannot be excluded. We therefore conclude that efficacy of psilocybin, Ayahuasca, or LSD is only one of the possible interpretations of large, positive changes in symptomatology for patients suffering from, for example, alcohol use disorder, anxiety with or without life-threatening disease, anxiety and/or depression with life-threatening cancer, treatment-resistant depression or major depressive disorder. We recommend care be taken to increase successful masking procedures and discuss alternative treatment designs to better control for potential masking influences.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
掩蔽的影响:关于迷幻药研究中安慰剂控制和掩蔽的系统回顾。
迷幻药辅助疗法越来越被认为是治疗各种精神疾病的有效干预手段。然而,在试验中很少有关于掩蔽成功率的评估报告。本系统综述的目的是评估迷幻辅助疗法研究中的安慰剂对照和遮蔽。按照严格的纳入和排除标准,我们使用六个数据库检索了 2010 年 1 月至 2023 年 3 月期间的九项研究(k = 9)。结果显示,近 78% 的研究最多只能达到 "较差 "的掩蔽成功率。同时,60%的活性安慰剂研究和 75% 的非活性安慰剂研究显示出较大的效应大小。换句话说,不能排除掩蔽的影响,包括良性未掩蔽。因此,我们得出结论,对于酗酒障碍、焦虑并伴有或不伴有危及生命的疾病、焦虑和/或抑郁并伴有危及生命的癌症、治疗耐受性抑郁或重度抑郁障碍等患者来说,西洛滨、死藤水或迷幻剂的疗效只是症状发生巨大、积极变化的可能解释之一。我们建议注意增加成功的掩蔽程序,并讨论替代治疗设计,以更好地控制潜在的掩蔽影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.30
自引率
7.10%
发文量
62
期刊最新文献
Associations Between Ayahuasca Use in Naturalistic Settings and Mental Health and Wellbeing Outcomes: Analysis of a Large Global Dataset. Factors Associated with Psychosis in 2098 Methamphetamine Users Admitted to 104 Outpatient Counseling Centers in 80 Cities in Turkey. Maintenance Intramuscular Ketamine-Assisted Psychotherapy, a Retrospective Chart Review of Efficacy, Adverse Events, and Dropouts from a Community Practice. Highs and Lows: A Mixed-Methods Analysis of the Impact of Adult Use Legalization on Medical Cannabis Patients. 24-Hour Induction of Transdermal Buprenorphine to Buprenorphine Extended-Release.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1